Loading...
Loading...
RLAY| Name | Value |
|---|---|
| Revenues | -0.0M |
| Cost of Revenue | 1.4M |
| Gross Profit | -1.4M |
| Operating Expense | 94.3M |
| Operating I/L | -92.2M |
| Other Income/Expense | 8.7M |
| Interest Income | 8.7M |
| Pretax | -83.5M |
| Income Tax Expense | 18.0M |
| Net Income/Loss | -83.5M |
Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on revolutionizing drug discovery, particularly in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), RLY-2608, a lead mutant-PI3Ka inhibitor program, and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2. Relay Therapeutics generates revenue through collaboration and license agreements with partners such as D. E. Shaw Research, LLC and Genentech, Inc. for the development and commercialization of its products.
